The role of the toxicologic pathologist in the biopharmaceutical industry

International Journal of Toxicology

Volumn 30, Issue 5, 2011, Pages 568-582

  Van Tongeren, Susan ^a   Fagerland, Jane A ^b   Conner, Michael W ^c   Diegel, Kelly ^d   Donnelly, Kevin ^e   Grubor, Branka ^f   Lopez Martinez, Alric ^g   Bolliger, Anne Provencher ^h   Sharma, Alok ⁱ   Tannehill Gregg, Sarah ^j   Turner, Patricia V ^k   Wancket, Lyn M ^l  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b ABBOTT LABORATORIES   (United States)

^c THERAVANCE INC   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e Covance Laboratories ^*  (United States)

^f NIBRI Novartis   (United States)

^g Huntingdon Life Sciences New Jersey   (United States)

^h CHARLES RIVER LABORATORIES   (United States)

ⁱ 206 Carnegie Center   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k UNIVERSITY OF GUELPH   (Canada)

^l OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

biopharmaceuticals; career development; drug development; toxicologic pathology

Indexed keywords

CAREER; CONFERENCE PAPER; DRUG INDUSTRY; DRUG RESEARCH; EDUCATION PROGRAM; HUMAN; PATHOLOGIST; SCIENCE; STAFF TRAINING; TOXICITY TESTING;

ANIMALS; BIOTECHNOLOGY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; PATHOLOGY, CLINICAL; RISK ASSESSMENT; STUDENTS; TOXICOLOGY; VETERINARIANS;

ANIMALIA;

EID: 80054826263     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811413304     Document Type: Conference Paper

References (76)

1. Ettlin RA, Bolon B, Pyrah I, Konishi Y, Black HE. Global recognition of qualified toxicologic pathologists: credential review as a potential route for recognizing the proficiency of pathologists involved in regulatory-type nonclinical studies. Toxicol Pathol. 2009 ; 37 (4). 553-561
2. Ettlin RA, Bolon B, Pyrah I, Konishi Y, Black HE. Global recognition of qualified toxicologic pathologists: credential review as a potential route for recognizing the proficiency of pathologists involved in regulatory-type nonclinical studies. Exp Toxicol Pathol. 2010 ; 62 (4). 413-422
3. American College of Veterinary Pathologists. American College of Veterinary Pathologists 2006 Salary Survey. 2007; http://www.acvp.org/news/ salsurv/ACVP-2006-Salary-Survey.pdf. Accessed October 19, 2010.
4. Ettlin RA, Bolon B, Pyrah I, Konishi Y, Black HE. Global recognition of qualified toxicologic pathologists: where we are now and where we need to go. Toxicol Pathol. 2008 ; 36 (5). 753-759
5. Ettlin RA, Bolon B, Pyrah I, Konishi Y, Black HE. Global recognition of qualified toxicologic pathologists: where we are now and where we need to go. Exp Toxicol Pathol. 2008 ; 60 (1). 1-8
6. Scudamore CL, Smith SH. Future directions in training veterinarians for careers in toxicological pathology in the United Kingdom. J Vet Med Educ. 2007 ; 34 (4). 450-457
7. Bolon B, Barale-Thomas E, Bradley A, et al. International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies. Toxicol Pathol. 2010 ; 38 (6). 984-992
8. Tannehill-Gregg SH, Sanderson TP, Minnema D, et al. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci. 2007 ; 98 (1). 258-270 (Pubitemid 47073837)
9. Cohen S, Mann A, Lear C, Mattson B. Arnold L. Toxicity of calcium phosphate precipitate and urinary amorphous precipitate toward rat bladder epithelial cells. Proc Am Assoc Cancer Res. 1995 ; 178: 36
10. Cohen SM, Arnold LL, Cano M, Ito M, Garland EM, Shaw RA. Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. Carcinogenesis. 2000 ; 21 (4). 783-792 (Pubitemid 30214037)
11. Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol. 2006 ; 34 (7). 903-920 (Pubitemid 46011143)
12. Cohen SM. Role of urinary physiology and chemistry in bladder carcinogenesis. Food Chem Toxicol. 1995 ; 33 (9). 715-730
13. Lehman-McKeeman LD, Caudill D. Quantitation of urinary alpha 2u-globulin and albumin by reverse-phase high performance liquid chromatography. J Pharmacol Methods. 1991 ; 26 (4). 239-247
14. Tannehill-Gregg SH, Dominick MA, Reisinger AJ, et al. Strain-related differences in urine composition of male rats of potential relevance to urolithiasis. Toxicol Pathol. 2009 ; 37 (3). 293-305
15. Capen C Casarett & Doulls Toxicology: The Basic Science of Poisons. 5 th ed. McGraw-Hill Professional, New York; 1996:617-640. Klaassen CD, ed. New York: McGraw-Hill Professional ; 1996: 617-640.
16. Curran PG, DeGroot LJ. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. Endocr Rev. 1991 ; 12 (2). 135-150
17. Schultze AE, Bounous DI, Bolliger AP. Veterinary clinical pathologists in the biopharmaceutical industry. Vet Clin Pathol. 2008 ; 37 (2). 146-158 (Pubitemid 352017739)
18. Fortune B, Wang L, Bui BV, Burgoyne CF, Cioffi GA. Idiopathic bilateral optic atrophy in the rhesus macaque. Invest Ophthalmol Vis Sci. 2005 ; 46 (11). 3943-3956 (Pubitemid 44264592)
19. Leedle R, Dubielzig R, Christian B. Bilateral optic atrophy in cynomolgus monkeys. Veterinary Pathol. 2008 ; 45 (5). 781
20. Whitney K, Schwartz A, OConnor J, Foley G, Garman R. Light microscopic changes of sciatic nerve in control beagle dogs in toxicity studies. Veterinary Pathol. 2009 ; 1081: 46
21. Geoly F, Kerlin R.. Raw data in nonclinical laboratory studies for the pharmaceutical industry: the pathologists view. Qual Assur J. 2004 ; 8 (3). 161-166 (Pubitemid 39120751)
22. PhRMA Annual Report. DC: Washington ; 2009 :
23. Burkhardt JE, Floyd E, Kerlin RL, Adler RR, Ochoa R, Reynolds JA. Commentary: a view on discovery pathology. Toxicol Pathol. 1999 ; 27 (4). 472-473 (Pubitemid 29357629)
24. Cockerell GL, McKim JM, Vonderfecht SL. Strategic importance of research support through pathology. Toxicol Pathol. 2002 ; 30 (1). 4-7 (Pubitemid 34194553)
25. Burkhardt JE, Ryan AM, Germann PG. Practical aspects of discovery pathology. Toxicol Pathol. 2002 ; 30 (1). 8-10 (Pubitemid 34194554)
26. Brosius FC, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009 ; 20 (12). 2503-2512
27. Tanzi RE. A promising animal model of Alzheimers disease. N Engl J Med. 1995 ; 332 (22). 1512-1513
28. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol. 2010 ; 28 (5). 455-462
29. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov. 2007 ; 6 (8). 636-649 (Pubitemid 47207750)
30. Boorman GA, Anderson SP, Casey WM, et al. Toxicogenomics, drug discovery, and the pathologist. Toxicol Pathol. 2002 ; 30 (1). 15-27 (Pubitemid 34194556)
31. International Committee on Harmonization. Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals m3(r2): note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals CPMP/ICH/286/95. 2009; http://www.ema.europa.eu/pdfs/human/ich/ 028695en.pdf. Accessed November 29, 2010.
32. Ochoa R Handbook of Toxicologic Pathology. 1. 2nd ed. San Diego: Academic Press; 2002:307-326. Haschek W Rouseaux C Wallig M, ed. San Diego: Academic Press ; 2002: 307-326.
33. Alden C, Smith P, Morton D. Application of genetically altered models as replacement for the lifetime mouse bioassay in pharmaceutical development. Toxicol Pathol. 2002 ; 30 (1). 135-138 (Pubitemid 34194571)
34. Testing for carcinogenicity of pharmaceuticals S1B,. Federal Register. 1995 ; (40). 11278-11281
35. Dose Selection for carcinogenicity studies of pharmaceuticals S1C, core guideline. Federal Register. 1995 ; 60 (40). 11278-11281
36. Guideline on the need for carcinogenicity studies of pharmaceuticals S1A. Federal Register. 1996 ; 8153: 61
37. Addendum to testing for carcinogenicity of pharmaceuticals S1B. Federal Register. 1997 ; 62 (233). 64260
38. Addendum to dose selection for carcinogenicity studies of pharmaceuticals S1C, core guideline. Federal Register. 1997 ; 62 (233). 64260
39. Cullen JM, Miller RT. The role of pathology in the identification of drug-induced hepatic toxicity. Expert Opin Drug Metab Toxicol. 2006 ; 2 (2). 241-247 (Pubitemid 46372367)
40. Rouseaux C, Haschek W, Wallig M Handbook of Toxicologic Pathology. Haschek W Rouseaux C Wallig M, ed. San Diego: Academic Press ; 2002: 3-4.
41. AdkinsCBooherLCulverDOccupational Exposure Limits-Do they have a future?2009; 1-12. Accessed October 19, 2010 fromhttp://www.ioha.net/assets/ files/OELGreen-Paper081909.pdf.
42. Title I-control of toxic substances. :
43. Environmental Protection Agency. OPPT reference: Series 870 health effects test guidelines. Docket ID No. EPA-HQ-OPPT-2009-0156.
44. amending Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH). 2010: 2003.
45. Bhalla V, Grimm PC, Chertow GM, Pao AC. Melamine nephrotoxicity: an emerging epidemic in an era of globalization. Kidney Int. 2009 ; 75 (8). 774-779
46. Ogasawara H, Imaida K, Ishiwata H, et al. Urinary bladder carcinogenesis induced by melamine in F344 male rats: correlation between carcinogenicity and urolith formation. Carcinogenesis. 1995 ; 16 (11). 2773-2777
47. Brown CA, Jeong KS, Poppenga RH, et al. Outbreaks of renal failure associated with melamine and cyanuric acid in dogs and cats in 2004 and 2007. J Vet Diagn Invest. 2007 ; 19 (5). 525-531 (Pubitemid 351202195)
48. Dobson RL, Motlagh S, Quijano M, et al. Identification and characterization of toxicity of contaminants in pet food leading to an outbreak of renal toxicity in cats and dogs. Toxicol Sci. 2008, 106 (1). 251-262
49. Choi L, Kwak MY, Kwak EH, et al. Comparative nephrotoxicitiy induced by melamine, cyanuric acid, or a mixture of both chemicals in either Sprague-Dawley rats or renal cell lines. J Toxicol Environ Health A. 2010 ; 73 ((21-22)). 1407-1419
50. Hau AK, Kwan TH, Li PK. Melamine toxicity and the kidney. J Am Soc Nephrol. 2009 ; 20 (2). 245-250
51. Woodward K General and Applied Toxicology. Ballantyne B Marrs TC Syversen T, ed. Basingstoke: MacMillan ; 1999: 1633-1652.
52. Evaluation of the Safety of Veterinary Medicinal Products for the Target Animal. European Commission, Luxembourg: ; 1999 :
53. Hurtt ME, Cappon GD, Browning A. Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food-producing animals. Food Chem Toxicol. 2003 ; 41 (5). 611-619 (Pubitemid 36349541)
54. Ibrahim C, Wike A Veterinary Pharmacovigilance. Woodward K, ed. Chichester, UK: Wiley-Blackwell ; 2008: 65-90.
55. Keck G, Pineau X Veterinary Pharmacovigilance. Woodward K, ed. Chichester, UK: Wiley-Blackwell ; 2008: 55-64.
56. Woodward K Veterinary Pharmacovigilance. Woodward K, ed. Chichester, UK: Wiley-Blackwell ; 2008: 297-345.
57. Woodward K Veterinary Pharmacovigilance. Woodward K, ed. Chichester, UK: Wiley-Blackwell ; 2008: 1946-1345.
58. Woodward K. Veterinary Pharmacovigilance. Woodward K, ed. Chichester, UK: Wiley-Blackwell ; 2008: 119-149.
59. Woodward K Veterinary Pharmacovigilance. Woodward K, ed. Chichester, UK: Wiley-Blackwell ; 2008: 109-117.
60. The Agencys Contribution to Sciences. Medicines, Health January. 2015 ; 26: 2010
61. Copley MP. Environmental Protection Agency risk assessment-process and toxicologic pathology. Toxicol Pathol. 1997 ; 25 (1). 68-71 (Pubitemid 27100561)
62. Merrill RA Casarett & Doulls Toxicology: The Basic Science of Poisons. 6 th ed.McGraw-Hill Professional, New York; 2001:1141-1153. Klaassen CD, ed. New York: McGraw-Hill Professional ; 2001: 1141-1153.
63. Chapter 54-Transportation, Sale, and Handling of Certain Animals Title 7-Agriculture (7 USC, 2131-2159). Washington, DC: US Government Printing Office ; 2007 :
64. Becker G. The Animal Welfare Act: Background and Selected Legislation. Washington, DC: Congressional Research Service ; 2009: 1-10.
65. Guide for the Care and Use of Laboratory Animals. 8 th ed. The National Academies Press, Washington, DC; 2010. The National Academies Press ; 2010 :
66. Administration FaD. 21 st ed. 21 VolPart 58, Good Laboratory Practice for Non-Clinical Laboratory Studies.
67. Principles of Good Laboratory Practice and Compliance Monitoring [C(97) 186)[ENV.MC/CHEM(98)17]. 1998 ;:
68. Dua PN, Jackson BA. Review of pathology data for regulatory purposes. Toxicol Pathol. 1988 ; 16 (4). 443-450 (Pubitemid 19030154)
69. Wolf DC, Mann PC. Confounders in interpreting pathology for safety and risk assessment. Toxicol Appl Pharmacol. 2005 ; 202 (3). 302-308 (Pubitemid 40164283)
70. International Committee on Harmonization. ICH Guidance E2A: Clinical Data Safety Management: Definitions and Standards for Expedited Reporting. 1995; http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500002749.pdf. Accessed November 29, 2010.
71. Haley P, Perry R, Ennulat D, et al. STP position paper: best practice guideline for the routine pathology evaluation of the immune system. Toxicol Pathol. 2005 ; 33 (3). 404 408-407
72. DeGeorge JJ, Ahn CH, Andrews PA, et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol. 1998 ; 41 (3). 173-185 (Pubitemid 28094040)
73. Boone L, Meyer D, Cusick P, et al. Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol. 2005 ; 34 (3). 182-188 (Pubitemid 41412481)
74. van der Greef J, McBurney RN. Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov. 2005 ; 4 (12). 961-967
75. Finch JM. Recent developments in preclinical toxicological pathology. Toxicol Appl Pharmacol. 2005 ; 207 ((2 suppl)). 209-213
76. EBVS Newsletter Spring 2011; www.ecvph.org/component/docman/doc-download/ 80-ebvsnewsletter2.. 2011 ;: 27